Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: An open‐label study extension of the SALIVA trial

Ähnliche Einträge

• Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double‐blind, placebo‐controlled trial
  von: Pierre Fayoux, et al.
  Veröffentlicht: (2024)
• Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: An open‐label study extension of the SALIVA trial
  Veröffentlicht: (2025)
• Oral language profiles and associated factors in children after neonatal arterial ischaemic stroke
  von: Laure Drutel, et al.
  Veröffentlicht: (2025)
• Functional outcomes in children and adolescents with neurodisability accessing music therapy: A scoping review
  von: Karen Twyford, et al.
  Veröffentlicht: (2024)
• Revisiting the meaning and the source of health‐related constructs and their applications in neurodisability
  Veröffentlicht: (2024)